Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(2):117–126. doi: 10.1111/j.1527-3458.2004.tb00008.x

Antinociceptive Properties of Fadolmidine (MPV‐2426), a Novel α2‐Adrenoceptor Agonist

Antti Pertovaara 1,✉
PMCID: PMC6741742  PMID: 15179442

ABSTRACT

Fadolmidine (MPV‐2426) is a novel α2‐adrenoceptor (α2‐AR) agonist developed for spinal analgesia. It is highly selective for α2‐ARs, but it lacks subtype selectivity. Due to its pharmacokinetic properties, it only poorly penetrates blood‐brain barrier or spreads from the site of injection within the central nervous system. By intrathecal (i.t.) administration to laboratory animals, fadolmidine produces dose‐dependent antinociception in healthy controls and in models of inflammatory, postoperative and neuropathic pain. Fadolmidine has been effective against various submodalities of pain such as heat pain, mechanical pain, and visceral pain. In general, the antinociceptive potency of fadolmidine, i.t., was equal to that of dexmedetomidine. At antinociceptive i.t. doses fadolmidine did not suppress motoneurons or responses to innocuous stimulation. It produced no hemody‐namic depression and considerably less sedation than dexmedetomidine. By peripheral administration fadolmidine had no or only a weak antinociceptive action, except following nerve injury, particularly that of the postganglionic sympathetic nerve fibers. Together these experimental animal studies indicate that i.t. administration of fadolmidine provides a segmentally restricted treatment of somatic and visceral pain, with only minor cardiovascular and sedative side effects. Additionally, peripheral administration of fadolmidine might provide a selective treatment for some hypersensitivity states that involve dysfunction of the sympathetic nervous system.

Keywords: α2‐Adrenoceptor agonist, Antinociception, Fadolmidine, MPV‐2426 Radolmidine

Full Text

The Full Text of this article is available as a PDF (121.2 KB).

REFERENCES

  • 1. Brennan TJ, Vandermeulen EP, Gebhart GF. Characterization of a rat model of incisional pain. Pain 1996;64:493–501. [DOI] [PubMed] [Google Scholar]
  • 2. Clark FM, Proudfit HK. Anatomical evidence for genetic differences in the innervation of the rat spinal cord by noradrenergic locus coeruleus neurons. Brain Res 1992;591:44–53. [DOI] [PubMed] [Google Scholar]
  • 3. Davis KD, Treede RD, Raja SN, Meyer RA, Campbell JN. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991;47:309–317. [DOI] [PubMed] [Google Scholar]
  • 4. DeSarro GB, Ascioti C, Froio F, Libri V, Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at α1‐ and α2‐adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987;90:675–685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Eisenach JC, Lavand'homme P, Tong C, et al. Antinociceptive and hemodynamic effects of a novel α2‐adrenergic agonist, MPV‐2426, in sheep. Anesthesiology 1999;91:1425–1436. [DOI] [PubMed] [Google Scholar]
  • 6. Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL. α2C‐adrenergic receptors mediate spinal analgesia and adrenergic‐opioid synergy. J Pharmacol Exp Ther 2002;300:282–290. [DOI] [PubMed] [Google Scholar]
  • 7. Hunter JC, Fontana DJ, Hedley LR, et al. Assessment of the role of α2‐adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 1997;122:1339–1344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Kawasaki Y, Kumamoto E, Furue H, Yoshimura M. α2‐Adrenoceptor‐mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology 2003;98:682–689. [DOI] [PubMed] [Google Scholar]
  • 9. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355–363. [DOI] [PubMed] [Google Scholar]
  • 10. Kingery WS, Davies MF, Maze M. Molecular mechanisms for the analgesic properties of alpha‐2 adrenergic agonists In: Borsook D, Ed. Molecular Neurobiology of Pain. Seattle : IASP Press, 1997;275–304. [Google Scholar]
  • 11. Lähdesmäki J, Scheinin M, Pertovaara A, Mansikka H. The α2A‐adrenoceptor subtype is not involved in inflammatory hyperalgesia or morphine‐induced antinociception. Eur J Pharmacol 2003;468:183–189. [DOI] [PubMed] [Google Scholar]
  • 12. Lakhlani PP, MacMillan LB, Guo TZ, et al. Substitution of a mutant α2A‐adrenergic receptor via “hit and run” gene targeting reveals the role of this subtype in sedative, analgesic and anesthetic‐sparing responses in vivo . Proc Natl Acad Sci USA 1997;94:9950–9955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Lehtimäki J, Haapalinna A, Korhonen T, et al. MPV‐2426, a novel α2‐adrenergic agonist for spinal analgesia. Fund Clin Pharmacol 1999;13(Suppl 1):380. [Google Scholar]
  • 14. Li X, Eisenach JC. α2A‐Adrenoceptor stimulation reduces capsaicin‐induced glutamate release from spinal cord synaptosomes. J Pharmacol Exp Ther 2001;299:939–944. [PubMed] [Google Scholar]
  • 15. Malmberg AB, Hedley LR, Jasper JR, Hunter JC, Basbaum AI. Contribution of α2 receptor subtypes to nerve injury‐induced pain and its regulation by dexmedetomidine. Br J Pharmacol 2001;132:1827–1836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Mansikka H, Lähdesmäki J, Scheinin M, Pertovaara A. α2A‐Adrenoceptors contribute to feedback inhibition of capsaicin‐induced hyperalgesia. Anesthesiology 2004; In press. [DOI] [PubMed]
  • 17. Olave MJ, Maxwell DJ. Neurokinin‐1 projection cells in the rat dorsal horn receive synaptic contacts from axons that possess α2C‐adrenergic receptors. J Neurosci 2003;23:6837–6846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Onttonen T, Pertovaara A. The antihyperalgesic effect of intrathecally administered MPV‐2426, a novel α2‐adrenoceptor agonist, in a rat model of postoperative pain. Anesthesiology 2000;92:1740–1745. [DOI] [PubMed] [Google Scholar]
  • 19. Onttonen T, Kalmari J, Pertovaara A. Selective and segmentally restricted antinociception induced by MPV‐2426, a novel α2‐adrenoceptor agonist, following intrathecal administration in the rat. Acta Anaesthesiol Scand 2000;44:1077–1082. [DOI] [PubMed] [Google Scholar]
  • 20. Pan YZ, Li DP, Pan HL. Inhibition of glutamatergic synaptic input to spinal lamina II(o) neurons by presynaptic α2‐adrenergic receptors. J Neurophysiol 2002;87:1938–1947. [DOI] [PubMed] [Google Scholar]
  • 21. Pertovaara A. Antinociception induced by α2‐adrenoceptor agonists, with special emphasis on medetomidine studies. Prog Neurobiol 1993;40:691–709. [DOI] [PubMed] [Google Scholar]
  • 22. Pertovaara A, Kalmari J. Comparison of the visceral antinociceptive effects of spinally administered MPV‐2426 (fadolmidine) andclonidine in the rat. Anesthesiology 2003;98:189–194. [DOI] [PubMed] [Google Scholar]
  • 23. Pertovaara A, Wei H. Attenuation of ascending nociceptive signals to the rostroventromedial medulla induced by α2‐adrenoceptor agonist, MPV‐2426, following intrathecal application in neuropathic rats. Anesthesiology 2000;92:1082–1092. [DOI] [PubMed] [Google Scholar]
  • 24. Pertovaara A, Hämäläinen MM, Kauppila T, Mecke E, Carlson S. Dissociation of the α2‐adrenergic antinociception from sedation following microinjection of medetomidine into the locus coeruleus in rats. Pain 1994;57:207–215. [DOI] [PubMed] [Google Scholar]
  • 25. Pertovaara A, Kauppila T, Jyväsjärvi E, Kalso E. Involvement of supraspinal and spinal segmental α2‐adrenergic mechanisms in the medetomidine‐induced antinociception. Neuroscience 1991;44:705–714. [DOI] [PubMed] [Google Scholar]
  • 26. Proudfit HK. Pharmacologic evidence for the modulation of nociception by noradrenergic neurons. Prog Brain Res 1988;77:357–370. [DOI] [PubMed] [Google Scholar]
  • 27. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991;251:1608–1610. [DOI] [PubMed] [Google Scholar]
  • 28. Spaulding TC, Venafro JJ, Ma MG, Fielding S. The dissociation of the antinociceptive effect of clonidine from supraspinal structures. Neuropharmacology 1979;18:103–105. [DOI] [PubMed] [Google Scholar]
  • 29. Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The α2A‐adrenergic receptor subtype mediates spinal analgesia evoked by α2A‐agonists and is necessary for spinal adrenergic‐opioid synergy. J Neurosci 1997;17:7157–7165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Talke P, Xu M, Paloheimo M, Kalso E. Effects of intrathecally administered dexmedetomidine, MPV‐2426 and tizanidine on EMG in rats. Acta Anaesthesiol Scand 2003;47:347–354. [DOI] [PubMed] [Google Scholar]
  • 31. Tan CM, Wilson MH, MacMillan LB, Kobilka BK, Limbird LE. Heterozygous α2A‐adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. Proc Natl Acad Sci USA 2002;99:12471–12476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Wei H, Jyväsjärvi E, Niissalo S, et al. The influence of chemical sympathectomy on pain responsivity and α2‐adrenergic antinociception in neuropathic animals. Neuroscience 2002;114:655–668. [DOI] [PubMed] [Google Scholar]
  • 33. Westlund KN, Carlton SM, Zhang D, Willis WD. Direct catecholaminergic innervation of primate spinothalamic tract neurons. J Comp Neurol 1990;299:178–186. [DOI] [PubMed] [Google Scholar]
  • 34. Xu M, Kontinen VK, Kalso E. Effects of radolmidine, a novel α2‐adrenergic agonist, compared with dexmedetomidine in different pain models in the rat. Anesthesiology 2000;93:473–481. [DOI] [PubMed] [Google Scholar]
  • 35. Xu M, Wei H, Kontinen VK, Kalso E, Pertovaara A. The dissociation of sedative from spinal antinociceptive effects following administration of a novel α2‐adrenoceptor agonist, MPV‐2426, in the locus coeruleus in the rat. Acta Anaesthesiol Scand 2000;44:648–655. [DOI] [PubMed] [Google Scholar]
  • 36. Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav 1985;22:845–858. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES